New pages

Jump to navigation Jump to search
New pages
Hide registered users | Hide bots | Show redirects
  • 22:57, 3 May 2024 ‎Xacduro- sulbactam and durlobactam (hist | edit) ‎[11,950 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...")
  • 18:20, 3 May 2024 ‎Perfluorhexyloctane (hist | edit) ‎[1,917 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}")
  • 15:29, 2 May 2024 ‎Trofinetide (hist | edit) ‎[74 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}")
  • 03:29, 2 May 2024 ‎Zavegepant (hist | edit) ‎[4,397 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...")
  • 21:51, 1 May 2024 ‎Omaveloxolone (hist | edit) ‎[5,828 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}")
  • 15:46, 1 May 2024 ‎Nirsevimab (hist | edit) ‎[15,269 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...")
  • 18:57, 30 April 2024 ‎Isosulfan Blue (hist | edit) ‎[5,962 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...")
  • 18:46, 30 April 2024 ‎Ibuprofen Lysine (hist | edit) ‎[15,666 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...")
  • 18:27, 30 April 2024 ‎Prussian blue (hist | edit) ‎[14,070 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...")
  • 18:14, 30 April 2024 ‎Botulism Antitoxin (hist | edit) ‎[18,011 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...")
  • 15:23, 29 April 2024 ‎Trastuzumab emtansine (hist | edit) ‎[40,575 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...")
  • 15:23, 25 April 2024 ‎Daprodustat (hist | edit) ‎[7,973 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")
  • 21:14, 24 April 2024 ‎Tranexamic (hist | edit) ‎[23,023 bytes] ‎Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")
  • 21:06, 24 April 2024 ‎Bexagliflozin (hist | edit) ‎[5,887 bytes] ‎Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}")
  • 03:47, 21 April 2024 ‎BRENZAVVY- bexagliflozin (hist | edit) ‎[12,281 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
  • 16:30, 19 April 2024 ‎Sparsentan (hist | edit) ‎[8,644 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
  • 19:33, 17 April 2024 ‎SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (hist | edit) ‎[2,387 bytes] ‎Hafiza Amna Qadeer (talk | contribs) (Created blank page)
  • 08:08, 17 April 2024 ‎Elranatamab-bcmm (hist | edit) ‎[32,900 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 ‎Palovarotene (hist | edit) ‎[39,234 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 ‎Pozelimab-bbfg (hist | edit) ‎[2,443 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 ‎Motixafortide (hist | edit) ‎[26,106 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 ‎Momelotinib (hist | edit) ‎[34,123 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:06, 17 April 2024 ‎Cipaglucosidase alfa-atga (hist | edit) ‎[38,322 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 ‎Etrasimod (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 ‎Zilucoplan (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Bimekizumab (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Vamorolone (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Mirikizumab-mrkz (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:03, 17 April 2024 ‎Toripalimab-tpzi (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:02, 17 April 2024 ‎Fruquintinib (hist | edit) ‎[25,648 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
  • 07:52, 17 April 2024 ‎Taurolidine, heparin (hist | edit) ‎[9,993 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
  • 07:43, 17 April 2024 ‎Repotrectinib (hist | edit) ‎[32,783 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
  • 07:32, 17 April 2024 ‎Efbemalenograstim alfa-vuxw (hist | edit) ‎[20,126 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
  • 05:50, 16 April 2024 ‎Capivasertib (hist | edit) ‎[34,175 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
  • 05:27, 16 April 2024 ‎Iptacopan (hist | edit) ‎[33,311 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
  • 07:24, 15 April 2024 ‎Vutrisiran (hist | edit) ‎[17,228 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
Retrieved from "https://www.wikidoc.org/index.php/Special:NewPages"